Related Experiment Video
Updated: Jan 6, 2026
Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
Published on: January 19, 2018
Pharmacokinetics and Tissue Distribution of DVDMS-2 in Tumor-bearing Mice
Tingting Li1, Haiyan Lv2, Liu Yang1
1Cancer Research Center, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Abstract:
DVDMS-2 is a novel candidate for photodynamic therapy of tumors. The purpose of the present study was to assess the distribution and elimination of DVDMS-2 in mice bearing hepatoma 22 tumors. DVDMS-2 (1, 2 and 4 mg kg-1 ) was injected intravenously into the mice, extracted from biological tissues and quantified using a fluorescence assay. The data obtained were processed with WinNonlin pharmacokinetic software. The fluorescence assay established for DVDMS-2 quantification was a rapid, reproducible, sensitive and specific method with good linearity. The pharmacokinetics of DVDMS-2 in tumor-bearing mice conformed to a two-compartment model. DVDMS-2 accumulated in tumor tissue to a greater extent than adjacent tissues (skin, muscle) and sustained a relatively high-level concentration 12 to 24 h following administration, which may be the optimal treatment time point. In conclusion, DVDMS-2 selectively accumulated in tumor tissue and was eliminated at a rapid rate in tumor-bearing mice, suggesting that DVDMS-2 may have few side effects, including skin phototoxicity. The present study established the pharmacokinetic characteristics of DVDMS-2, which may be beneficial in future clinical study.
Insights
DVDMS-2, a novel photodynamic therapy agent, shows selective accumulation in tumors and rapid elimination in mice. This suggests potential for effective cancer treatment with minimal side effects.
Area of Science:
- Pharmacology
- Oncology
- Biomedical Engineering
Background:
- Photodynamic therapy (PDT) is a promising cancer treatment modality.
- Novel photosensitizers are continuously being developed to improve PDT efficacy and safety.
- DVDMS-2 is a new candidate for PDT with potential therapeutic benefits.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of DVDMS-2 in tumor-bearing mice.
- To determine the distribution and elimination patterns of DVDMS-2 in vivo.
- To identify optimal administration time points for DVDMS-2 in photodynamic therapy.
Main Methods:
- Intravenous administration of DVDMS-2 (1, 2, and 4 mg/kg) to mice with hepatoma 22 tumors.
- Quantification of DVDMS-2 in biological tissues using a validated fluorescence assay.
- Pharmacokinetic analysis using WinNonlin software and a two-compartment model.
Main Results:
- A rapid, reproducible, sensitive, and specific fluorescence assay was developed for DVDMS-2.
- DVDMS-2 exhibited a two-compartment pharmacokinetic model in tumor-bearing mice.
- DVDMS-2 selectively accumulated in tumor tissue over adjacent tissues, maintaining high concentrations for 12-24 hours post-administration.
Conclusions:
- DVDMS-2 demonstrates selective tumor accumulation and rapid elimination in vivo.
- The pharmacokinetic profile suggests a favorable safety profile, potentially minimizing side effects like skin phototoxicity.
- These findings support further clinical investigation of DVDMS-2 for cancer photodynamic therapy.
